Tax Implications of Brexit on the Pharmaceutical Industry

This Guidance Note outlines some key tax implications of Brexit on the pharmaceutical industry. The EU and UK have agreed the terms of a future economic partnership in the EU-UK Trade and Cooperation Agreement, with only days left before the end of the transition period.

Like Comment

This Guidance Note outlines some key tax implications of Brexit on the pharmaceutical industry. The EU and UK have agreed the terms of a future economic partnership in the EU-UK Trade and Cooperation Agreement, with only days left before the end of the transition period.

The agreement provides some clarity and certainty on VAT, customs, and excise duty in relation to trade between EU and UK. The changes to indirect tax for UK/EU trade are of upmost significance but the impact on Corporation Tax are also of importance. This Note does not cover every aspect of UK and international taxation that could be affected but draws out those considered to be of greatest significance for the Life Sciences sector.

You can access the guidance note here:

GNT 35 Tax Implications of Brexit on the Pharmaceutical Industry (knak.io)

FTI Consulting

In a rapidly changing tax landscape, our professionals deliver client-centric expert-led services focused on mitigating tax risk and minimising cost. As leaders in their field, the FTI senior management team members are qualified in accounting, tax, law, and surveying, and work alongside valuations and technology experts and economists to address clients’ most complex tax challenges. FTI’s team is one of the independent tax practices in the UK, and as a member of the WTS Global Network, they work alongside world-leading tax consultancies and law firms to provide solutions to clients at a cross-jurisdictional level. Our services include: Corporate tax compliance and reporting, International tax, Transaction tax, Restructuring tax advisory, Transfer pricing, Tax depreciation, Employment tax and reward, VAT and indirect tax compliance, R&D incentives, patent box and IP strategy, Real estate tax, Tax strategy and regulation advisory, Tax technology advisory.
7 Contributions
1 Followers
0 Following

No comments yet.